Presbyopia Market to Register Incremental Growth During the Forecast Period | AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire

Presbyopia Market
In 2023, the market size of presbyopia was highest in the US among the 7MM, accounting for approximately USD 9,473 million. The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of presbyopia.

The pipeline is dynamic, consisting of Orasis Pharmaceuticals (PresbiDrops), Eyenovia (MicroLine), AbbVie (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (Brimochol), and others therapies most of which are expected to launch during the forecast period. Emerging therapies can potentially create a significant positive shift in the Presbyopia market size. Some of the leading pharma and biotech giants such as AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire Pharma, and others are actively working in the Presbyopia Market.

DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Presbyopia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Presbyopia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Presbyopia Overview

Presbyopia is a natural age-related condition where the eyes progressively find it harder to focus on nearby objects. The term itself originates from Greek, meaning “old age sight.” Typically, individuals start experiencing the effects of presbyopia around the age of 40, as the lenses in their eyes lose flexibility due to the aging process.

In the case of presbyopia, the crystalline lens of the eye undergoes changes in its shape. These alterations impair the ability to focus on objects that are close. Although presbyopia might seem to develop abruptly, the decline in vision actually occurs over a span of several years, with the process initiating as early as childhood.

Symptoms of presbyopia include the need to hold reading materials further away, experiencing blurred vision at a typical reading distance, feeling eye strain, and developing headaches when engaging in close work. This condition is a natural part of aging, where the eye’s inability to focus light directly onto the retina results from the hardening of the natural lens. Additionally, the aging process affects the muscle fibers surrounding the lens, making it more challenging for the eye to focus on objects up close. The consequence of an inefficient lens is that light focuses behind the retina, leading to impaired vision for nearby objects.

Presbyopia Market Key Facts

The total diagnosed prevalence of presbyopia is on the rise, driven by various factors such as growing geriatric population less outdoor activities. Additionally, advancements in healthcare and technology have led to better diagnosis and awareness of the condition, contributing to higher reported prevalence rates in the 7MM.
The impact of COVID-19 on presbyopia has been multifaceted. While the pandemic has led to increased screen time due to remote work and online activities, potentially exacerbating presbyopia symptoms, it has also disrupted routine eye care services, leading to delayed diagnosis and treatment for some individuals.
Approved therapies for treating presbyopia are limited and include AbbVie’s VUITY and the recently approved Orasis Pharmaceutical’s QLOSI for treating presbyopia in adults.
In 2023, the market size of presbyopia was highest in the US among the 7MM, accounting for approximately USD 9,473 million. The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of presbyopia.
Nearly half of presbyopia patients remain uncorrected, while existing treatment options may not comprehensively fulfill the visual requirements of all individuals affected by presbyopia. This underscores the necessity for improved access to effective treatments and vision correction options to enhance the quality of life for individuals affected by presbyopia.
However, emerging therapies such as Ocuphire Pharma (Nyxol), Visus therapeutics (VTI-001/Brimochol), Lenz Therapeutics (LENZ100), and several others are investigating their candidates for the management of presbyopia in the 7MM.

Presbyopia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Presbyopia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Presbyopia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Presbyopia Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

The Report Covers the Presbyopia Epidemiology, Segmented as –

Total Diagnosed Cases of Presbyopia in the 7MM

Total Age-Specific Cases of Presbyopia in the 7MM

Total Prevalent Cases of Presbyopia in the 7MM

Gender-Specific Cases of Presbyopia in the 7MM

Severity-Specific Cases of Presbyopia in the 7MM

Presbyopia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Presbyopia market or expected to be launched during the study period. The analysis covers the Presbyopia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Presbyopia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Presbyopia Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/presbyopia-market

Presbyopia Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Presbyopia. Several drugs are being developed as topical ophthalmic solutions to treat Presbyopia. These drops can broadly be divided into two categories: miotic-based eye drops and lens restoration drops.

Currently, Orasis Pharmaceuticals is leading the therapeutics market with its Presbyopia drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Presbyopia Therapeutic Market Include:

AbbVie

Cellix Bio

Eyenovia

Glaukos Corporation

JIXING Pharmaceuticals

LENZ Therapeutics

Novartis

Ocuphire Pharma

Orasis Pharmaceuticals

Visus Therapeutics

Vyluma

And Many Others

Presbyopia Emerging and Marketed Drugs Covered in the Report Include:

AGN-241622: AbbVie

CSF-1 (PresbiDrops): Orasis Pharmaceuticals

GLK-302 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

LNZ100 (Aceclidine 1.75%): LENZ Therapeutics

MicroLine (Pilocarpine Ophthalmic): Eyenovia

Nyxol: Ocuphire Pharma

UNR844 (Lipoic Acid Choline Ester): Novartis

VT-101 (Brimochol): Visus Therapeutics

Vuity: AbbVie

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/presbyopia-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Presbyopia Competitive Intelligence Analysis

4. Presbyopia Market Overview at a Glance

5. Presbyopia Disease Background and Overview

6. Presbyopia Patient Journey

7. Presbyopia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Presbyopia Treatment Algorithm, Current Treatment, and Medical Practices

9. Presbyopia Unmet Needs

10. Key Endpoints of Presbyopia Treatment

11. Presbyopia Marketed Products

12. Presbyopia Emerging Drugs and Latest Therapeutic Advances

13. Presbyopia Seven Major Market Analysis

14. Attribute Analysis

15. Presbyopia Market Outlook (In US, EU5, and Japan)

16. Presbyopia Access and Reimbursement Overview

17. KOL Views on the Presbyopia Market

18. Presbyopia Market Drivers

19. Presbyopia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/presbyopia-market

The total diagnosed prevalence of presbyopia is on the rise, driven by various factors such as growing geriatric population less outdoor activities. Additionally, advancements in healthcare and technology have led to better diagnosis and awareness of the condition, contributing to higher reported prevalence rates in the 7MM.The impact of COVID-19 on presbyopia has been multifaceted. While the pandemic has led to increased screen time due to remote work and online activities, potentially exacerbating presbyopia symptoms, it has also disrupted routine eye care services, leading to delayed diagnosis and treatment for some individuals.Approved therapies for treating presbyopia are limited and include AbbVie’s VUITY and the recently approved Orasis Pharmaceutical’s QLOSI for treating presbyopia in adults.In 2023, the market size of presbyopia was highest in the US among the 7MM, accounting for approximately USD 9,473 million. The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of presbyopia.Nearly half of presbyopia patients remain uncorrected, while existing treatment options may not comprehensively fulfill the visual requirements of all individuals affected by presbyopia. This underscores the necessity for improved access to effective treatments and vision correction options to enhance the quality of life for individuals affected by presbyopia.However, emerging therapies such as Ocuphire Pharma (Nyxol), Visus therapeutics (VTI-001/Brimochol), Lenz Therapeutics (LENZ100), and several others are investigating their candidates for the management of presbyopia in the 7MM.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×